WESTMINSTER, Colo., Nov. 20 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH) today announced that the Company has been
selected for inclusion in the NASDAQ Biotechnology Index (NBI), effective
as of the market's open today, November 20, 2006.
"We are very pleased to be included in the NASDAQ Biotechnology Index
and believe that our selection is further recognition of our consistent
progress and recent achievements" said Paul L. Berns, President and Chief
Executive Officer. "We look forward to continuing to execute on our
strategy to deliver innovative medicines that enhance and extend the lives
of cancer patients."
The NBI was launched in 1993 and includes biotechnology and
pharmaceutical companies listed on the NASDAQ National Market that meet
minimum requirements for market value, average daily share volume and
seasoning as a public company. The NBI is ranked on a semi-annual basis in
May and November and serves as the basis for the iShares Nasdaq
Biotechnology Index Fund (Amex: IBB). For more information about the Nasdaq
Biotechnology Index, including eligibility criteria, visit http://www.nasdaq.com.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused
on the development and commercialization of small molecule therapeutics for
the treatment of cancer. The Company has two product candidates in
late-stage clinical development: EFAPROXYN (efaproxiral), a radiation
sensitizer currently under evaluation in a pivotal Phase 3 trial in women
with brain metastases originating from breast cancer, and PDX
(pralatrexate), a novel, next generation antifolate currently under
evaluation in a pivotal Phase 2 trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The Company is also evaluating RH1,
a targeted chemotherapeutic agent, in a Phase 1 trial in patients with
advanced solid tumors. For additional information, please visit the
Company's website at http://www.allos.com.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, Inc., +1-720-540-5227,
jneiman@allos.com
|
